Key Takeaways:
Scribe Therapeutics raised $128.7 million in an upsized initial public offering, pricing 8.58 million shares at $15 each, as the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna debuted on the Nasdaq.
"The strong demand reflects investor appetite for in vivo gene-editing platforms with clear clinical pathways in large addressable markets," said Tom Brennan, IPO analyst at Edgen.
The offering, upsized from an undisclosed initial target, priced at the high end of the range. Underwriters have a 30-day option to purchase up to an additional 1.29 million shares. Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo Securities acted as joint book-running managers.
The listing opens a path for other gene-editing companies to test public market appetite in the second half of 2026. Scribe's lead candidate, STX-1150, targets elevated LDL-C by epigenetically silencing the PCSK9 gene, a mechanism that could compete with existing statin and PCSK9 inhibitor therapies in a multi-billion-dollar cardiometabolic market.
The Alameda, California-based company sold all shares in the offering, with proceeds earmarked for advancing its pipeline of in vivo CRISPR therapies. Scribe's CRISPR by Design platform engineers Cas enzymes and guide RNAs to create therapies that modify gene expression without cutting DNA, a safety advantage the company says could broaden the addressable patient population.
Sanofi, already a strategic collaborator, agreed to purchase 500,000 shares at the same $15 price in a concurrent private placement expected to close July 27. The IPO is not contingent on the private placement. Sanofi and Eli Lilly are among Scribe's pharmaceutical partners, providing both validation and potential commercialization pathways.
Scribe's initial programs focus on atherosclerotic cardiovascular disease, targeting elevated LDL cholesterol, lipoprotein(a) and triglycerides — conditions affecting tens of millions of patients in the U.S. alone. The company's epigenetic silencing approach offers a potential durability advantage over daily statins or periodic injectable PCSK9 inhibitors, though clinical data remain early-stage.
The IPO market for biotech has shown signs of recovery after a prolonged downturn, with investors favoring companies that combine platform technology with clear clinical milestones. Scribe's Doudna pedigree and Big Pharma partnerships distinguish it from earlier-stage gene-editing peers that went public in the 2020-2021 boom.
This article is for informational purposes only and does not constitute investment advice.
